Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Protalix Biotherapeutics (NYSEMKT:PLX) is the #1 top healthcare stock out of 1139 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Protalix Biotherapeutics (NYSEMKT:PLX) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: C.

Protalix Biotherapeutics (NYSEMKT:PLX) has a Due Diligence Score of 23, which is -3 points lower than the healthcare sector average of 26. Although this number is below the industry average, our proven quant model rates PLX as a "A".It passed 7 out of 33 due diligence checks and has weak fundamentals. Protalix Biotherapeutics has seen its stock return 116.1% over the past year, overperforming other healthcare stocks by 172 percentage points.

Protalix Biotherapeutics has an average 1 year price target of $15.00, an upside of 488.24% from Protalix Biotherapeutics's current stock price of $2.55.

Protalix Biotherapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Protalix Biotherapeutics, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Bioventus (NASDAQ:BVS) is the #2 top healthcare stock out of 1139 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 15, which is -11 points lower than the healthcare sector average of 26. Although this number is below the industry average, our proven quant model rates BVS as a "A".It passed 5 out of 33 due diligence checks and has weak fundamentals. Bioventus has seen its stock return 74.83% over the past year, overperforming other healthcare stocks by 130 percentage points.

Bioventus has an average 1 year price target of $14.33, an upside of 91.11% from Bioventus's current stock price of $7.50.

Bioventus stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Bioventus, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Pediatrix Medical Group (NYSE:MD) is the #3 top healthcare stock out of 1139 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Pediatrix Medical Group (NYSE:MD) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: B.

Pediatrix Medical Group (NYSE:MD) has a Due Diligence Score of 11, which is -15 points lower than the healthcare sector average of 26. Although this number is below the industry average, our proven quant model rates MD as a "A".It passed 3 out of 33 due diligence checks and has weak fundamentals. Pediatrix Medical Group has seen its stock return 32.89% over the past year, overperforming other healthcare stocks by 89 percentage points.

Pediatrix Medical Group has an average 1 year price target of $16.75, an upside of 39.58% from Pediatrix Medical Group's current stock price of $12.00.

Pediatrix Medical Group stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Pediatrix Medical Group, 16.67% have issued a Strong Buy rating, 16.67% have issued a Buy, 66.67% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 66 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of N/A, which is N/A percentage points lower than the healthcare sector average of 2.16%.

Siga Technologies's dividend payout ratio of 72.3% indicates that its dividend yield is sustainable for the long-term.

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 12.7%, which is 11 percentage points higher than the healthcare sector average of 2.16%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 30.1% indicates that its high dividend yield is sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 8.22%, which is 6 percentage points higher than the healthcare sector average of 2.16%. Spok Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 168.9% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -1.81% in the last day, and down -3.37% over the last week. Humana was the among the top losers in the healthcare sector, dropping -7.02% yesterday.

Shares of health insurance stocks are trading lower in sympathy with UnitedHealth, which reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates on Thursday.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Puma Biotechnology (NASDAQ:PBYI) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -44.68% in the past year. It has overperformed other stocks in the healthcare sector by 11 percentage points.

Biogen (NASDAQ:BIIB) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 100, which is 84 points higher than the healthcare sector average of 16. It passed 7 out of 7 valuation due diligence checks.

Biogen's stock has dropped -39.99% in the past year. It has overperformed other stocks in the healthcare sector by 16 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -2.9% in the past year. It has overperformed other stocks in the healthcare sector by 53 percentage points.

52.34% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 64.54% over the next year.

4.52% of healthcare stocks have a Zen Rating of A (Strong Buy), 13.08% of healthcare stocks are rated B (Buy), 45.11% are rated C (Hold), 26.41% are rated D (Sell), and 10.88% are rated F (Strong Sell).